Image
![ZENEO](/sites/default/files/2023-11/Injection%20ZENEO%20sur%20tiers%20a%20traver%20s%20un%20v%C3%AAtement-Cr%C3%A9dit%20Crossject.jpg)
Date de parution
Sommaire ou résumé
The ODDO BHF analysts rated Crossject as “Outperform” with a price target of €7.10, citing the significant advantages associated with the company’s needle-free ZENEO® device, which enables easily administered injections to be delivered by patients and untrained caregivers in a fraction of a second in emergency situations. Crossject’s contract with the U.S. Biomedical Advanced Research and Development Authority (BARDA) to procure ZEPIZURE®, previously known as ZENEO® Midazolam, for nerve agent-induced epileptic seizures, is an important validation of the platform, the analysts said.
PDF du document